MEF2B and rheumatoid arthritis: The results of our Taxonomy3 analyses present an opportunity for initiation of drug discovery programmes for treating RA, the identified novel targets (e.g. MEF2B) benefitting from the increased chances of success due to their genetic association with the disease, subject to further experimental validation.